Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-Derived CD19 CAR-T for Lymphoid Malignancies Post-Allo HSCT
NCT03579888Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RPM CD19-mbIL15-CAR-T in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 15 years and Maximum tolerated dose at 30 days. Started Jun 2020; status: terminated.
02
Drugs
RPM CD19-mbIL15-CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03579888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579888.